HDAC4 in ischemic stroke: mechanisms and therapeutic potential

• Published in: Clinical epigenetics Vol. 10; no. 1; p. 117
• Main Authors: Kong, Qingsheng, Hao, Yongnan, Li, Xin, Wang, Xin, Ji, Bingyuan, Wu, Yili
• Format: Journal Article
• Language: English
• Published: Germany BioMed Central Ltd 12.09.2018; BioMed Central; BMC
• Subjects: Angiogenesis; Apoptosis; Brain Ischemia - drug therapy; Brain Ischemia - genetics; Care and treatment; Cell death; Cell growth; Chromatin; Disease; Diuretics; Down-Regulation; Epigenesis, Genetic; Gangrene; Gene expression; Genetic aspects; HDAC4; Histone deacetylase; Histone Deacetylase Inhibitors - therapeutic use; Histone Deacetylases - genetics; Humans; Ischemia; Ischemic stroke; Neurogenesis; Pathogenesis; Patient outcomes; Repressor Proteins - genetics; Review; Stem cells; Stroke; Stroke (Disease); Stroke - drug therapy; Stroke - genetics; Thrombolysis; United States > US; HDAC4; Angiogenesis; Ischemic stroke; Cell death; Neurogenesis
• ISSN: 1868-7075; 1868-7083; 1868-7083; 1868-7075
• DOI: 10.1186/s13148-018-0549-1

Stroke is one of the leading causes of death and disability worldwide, and the majority of the cases are ischemic stroke. However, it still lacks effective treatment except for thrombolytic therapy in an extremely narrow time window. Increased evidence suggests that histone deacetylase 4 (HDAC4) was dysregulated in ischemic stroke, which plays a key role in the pathogenesis of ischemic stroke and post-stroke recovery by affecting neuronal death, angiogenesis, and neurogenesis. Therefore, we aim to review the dysregulation of HDAC4 in ischemic stroke and the role of dysregulated HDAC4 in the pathogenesis of ischemic stroke. Furthermore, the therapeutic potential of modulating HDAC4 in ischemic stroke is discussed.